- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Obinutuzumab – March 2018
Obinutuzumab: Solution for I.V. infusion, 1000 mg in 40 mL; GAZYVA®
Last updated
9 November 2018